GlassScriptPhysician profile
Maria Braun
NPI 1508828229
$1,665.64
in general payments reported to CMS, 2019-2025
20 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $76.06 · 2021: $14.14 · 2022: $121 · 2023: $89.86 · 2024: $308 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $362.42 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $361.25 | 2021-2025 | Synthroid |
| Glaxosmithkline, LLC. | $168.66 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $168.57 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $132.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $74.82 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $69.23 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $51.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.23 | 2019 | |
| Shire North American Group INC | $36.14 | 2019 | |
| Amgen INC. | $32.36 | 2019-2020 | |
| Pfizer INC. | $24.40 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $24.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.90 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $20.96 | 2024 | Nexletol |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Appliedvr INC | $19.40 | 2025 | Relievrx |
| Ibsa Pharma INC. | $19.27 | 2020 | |
| Allergan, INC. | $13.43 | 2019 | |
| Daiichi Sankyo INC. | $11.37 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Braun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.